Raptor Pharmaceutical plans to price public offering of common stock

Offering also has an over-allotment option, funds development programs

By Devika Patel

Knoxville, Tenn., Sept. 7 - Raptor Pharmaceutical Corp. will price an underwritten public offering of its common shares, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission. The deal also has a 30-day greenshoe.

JMP Securities LLC is the sole bookrunning manager, and Canaccord Genuity and Cowen and Co. are co-lead managers.

Proceeds will be used for the company's commercial and precommercial efforts, clinical and preclinical development programs and other general corporate activities.

Raptor is a Novato, Calif., biotechnology company that bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein and related proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.